121 related articles for article (PubMed ID: 18638631)
1. Desonide foam 0.05%: safety in children as young as 3 months.
Hebert AA;
J Am Acad Dermatol; 2008 Aug; 59(2):334-40. PubMed ID: 18638631
[TBL] [Abstract][Full Text] [Related]
2. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB; Gold MH; Zib B; Davis MW;
J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
[TBL] [Abstract][Full Text] [Related]
3. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis.
Eichenfield LF; Basu S; Calvarese B; Trancik RJ
Pediatr Dermatol; 2007; 24(3):289-95. PubMed ID: 17542883
[TBL] [Abstract][Full Text] [Related]
4. Hydrocortisone butyrate 0.1% cream (proprietary lipid rich cream vehicle) does not significantly suppress hypothalamic-pituitary-adrenal axis and is effective in pediatric patients 3 months and older with extensive atopic dermatitis.
Abramovits W; Oquendo M
Skinmed; 2010; 8(3):150-4. PubMed ID: 21137620
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis.
Hebert AA; Cook-Bolden FE; Basu S; Calvarese B; Trancik RJ;
J Drugs Dermatol; 2007 Feb; 6(2):175-81. PubMed ID: 17373176
[TBL] [Abstract][Full Text] [Related]
6. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis.
Lucky AW; Grote GD; Williams JL; Tuley MR; Czernielewski JM; Dolak TM; Herndon JH; Baker MD
Cutis; 1997 Mar; 59(3):151-3. PubMed ID: 9071556
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis].
Lebrun-Vignes B; Legrain V; Amoric J; Taïeb A
Ann Dermatol Venereol; 2000; 127(6-7):590-5. PubMed ID: 10930856
[TBL] [Abstract][Full Text] [Related]
8. An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis.
Schlessinger J; Miller B; Gilbert RD; Plott RT;
Arch Dermatol; 2006 Dec; 142(12):1568-72. PubMed ID: 17178982
[TBL] [Abstract][Full Text] [Related]
9. Desonide foam: a review.
Parish D; Scheinfeld N
Drugs Today (Barc); 2008 Jan; 44(1):55-62. PubMed ID: 18301804
[TBL] [Abstract][Full Text] [Related]
10. Overview on desonide 0.05%: a clinical safety profile.
Wong VK; Fuchs B; Lebwohl M
J Drugs Dermatol; 2004; 3(4):393-7. PubMed ID: 15303783
[TBL] [Abstract][Full Text] [Related]
11. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
12. Practical advantages of desonide hydrogel in the management of atopic dermatitis. Introduction.
Kircik LH
Cutis; 2011 Jul; 88(1 Suppl):4-6. PubMed ID: 21916150
[No Abstract] [Full Text] [Related]
13. Self-reported participant experience with desonide hydrogel in the treatment of mild to moderate atopic dermatitis.
Kerney DL; Ford RO; Gotz V
Cutis; 2011 Jul; 88(1 Suppl):18-24. PubMed ID: 21916152
[TBL] [Abstract][Full Text] [Related]
14. The importance of vehicle properties to patients with atopic dermatitis.
Trookman NS; Rizer RL; Ho ET; Ford RO; Gotz V
Cutis; 2011 Jul; 88(1 Suppl):13-7. PubMed ID: 21919229
[TBL] [Abstract][Full Text] [Related]
15. Moisturizing advantages of desonide hydrogel in treating atopic dermatitis.
Trookman NS; Rizer RL; Ho ET; Ford RO; Gotz V
Cutis; 2011 Jul; 88(1 Suppl):7-12. PubMed ID: 21916151
[TBL] [Abstract][Full Text] [Related]
16. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
Paller AS; Eichenfield LF; Kirsner RS; Shull T; Jaracz E; Simpson EL;
Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
[TBL] [Abstract][Full Text] [Related]
17. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects.
Matheson R; Kempers S; Breneman D; Draelos Z; Johnson CE; Loss R; Hogan DJ; Schoenfeld R; Checketts S; Kircik L; Fivenson D; Hebert AA; Williams J; Hamlin R; Groisser D; Piacquadio D
J Drugs Dermatol; 2008 Mar; 7(3):266-71. PubMed ID: 18380208
[TBL] [Abstract][Full Text] [Related]
18. Hypothalamic-pituitary-adrenal function in children with atopic dermatitis treated with clobetasone butyrate and its clinical evaluation.
Boner AL; Richelli C; De Stefano G; Valletta EA; Ferrari S; Mengoni M
Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):118-20. PubMed ID: 2985514
[TBL] [Abstract][Full Text] [Related]
19. Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance.
Yentzer BA; Camacho FT; Young T; Fountain JM; Clark AR; Feldman SR
J Drugs Dermatol; 2010 Apr; 9(4):324-9. PubMed ID: 20514788
[TBL] [Abstract][Full Text] [Related]
20. Topical fluticasone propionate lotion does not cause HPA axis suppression.
Hebert AA; Friedlander SF; Allen DB
J Pediatr; 2006 Sep; 149(3):378-82. PubMed ID: 16939752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
